Hormone Therapy
PCOS incidence remains stable, but age at diagnosis shifts younger
U.S. polycystic ovary syndrome incidence remained stable from 2006 to 2019, but prevalence was almost double prior estimates, according to data published in the American Journal of Obstetrics and Gynecology.
Testosterone therapy may benefit men with diabetes and obesity, but remains controversial
An increasing number of studies are reporting that testosterone therapy may not only normalize testosterone levels for men, but may also provide cardiometabolic benefits.
Are providers too cautious with prescribing testosterone therapy?
Providers are too cautious with testosterone therapy. The myth is that increasing testosterone level will cause prostate cancer. If you start with a myth, you have to disprove that myth with a trial that is probably too big to ever conduct and that nobody will ever fund. Although repeated studies have shown no risks with testosterone therapy, those small studies are never looked at.
Earlier age at menopause, later HT initiation linked to Alzheimer’s disease vulnerability
Being younger at menopause onset and initiating hormone therapy after more than 5 years were both linked to increased tau vulnerability among women, according to a cross-sectional study published in JAMA Neurology.
American Cancer Society presents researcher of the year award
Vanessa B. Sheppard, PhD, received American Cancer Society’s 2022 Researcher of the Year Award.
Should estrogen therapy be used by breast cancer survivors?
For medicine to advance, entrenched paradigms must yield to new evidence. The widely held belief that menopausal hormone therapy causes breast cancer, and thus should never be given to breast cancer survivors, must be reassessed.
Long-term studies reveal what women can expect during menopause
More than ever before, women today may have more information — and misinformation — about menopause.
Menopausal hormone therapy does not increase lung cancer risk
Women using hormone therapy for menopause symptoms did not have a greater risk for lung cancer than their untreated peers, and may have had lower risk with higher HT dosage and duration, according to study data published in Menopause.
Women on GH therapy have lower IGF-I levels, experience more adverse effects than men
Women with growth hormone deficiency treated with GH therapy have lower insulin-like growth factor I levels at both baseline and follow-up and experience more adverse events than men, according to study data.
Transgender patients on masculinizing hormones face greater androgenetic alopecia risk
Transgender and gender-diverse patients receiving masculinizing hormone therapy have 2.5 times the rate of androgenetic alopecia incidences compared with cisgender women, according to a study.